Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review

Laribi, Kamel; Sobh, Mohamad; Gourichon, David; Materre, Alix Baugier de

doi:10.1007/s00277-020-04375-x

Cited by 15 publications

(11 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of age should be evaluated in the light of co-existing co-morbidities, with the aim of selecting patients eligible for intensive chemotherapy and, if needed, allogeneic transplantation. Nevertheless, most new targeted agents are also indicated for the treatment of older patients with AML (16)(17)(18), therefore accurate molecular characterization of the disease is desirable regardless of age (19).…”

Section: Comments From the Scientific Steering Committeementioning

confidence: 99%

“…In patients with specific genetic alterations, cytomorphological examination of BM, and accurate evaluation of blast infiltration, according to the current guidelines, is of paramount importance to guide diagnosis and assess response to treatment (6). The committee also emphasizes that in the case of t(15;17), t(8;21), inv (16), or t(16;16) and their respective fusion genes, the diagnosis of AML can be made even if the BM blast percentage is less than 20%.…”

Section: Comments From the Scientific Steering Committeementioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey

et al. 2022

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous disease with a wide variety of clinical presentations, morphological features, and immunophenotypes. The diagnostic approaches to AML that are adopted in Italy have been explored using an online Delphi-based process to expand the global discussion on mandatory tests for the correct diagnosis and, consequently, for optimal management of AML in clinical practice. The final results of the panel of Italian hematologists involved in this work highlight the importance of genetic evaluation for classification and risk stratification and firmly establish that karyotyping, fluorescence in situ hybridization in cases with non-evaluable karyotype, and molecular tests must be performed in every case of AML, regardless of age. Obtaining clinically relevant genetic data at diagnosis is the basis for the success of patient-tailored therapy. The Italian specialists also confirm the role of multidisciplinary diagnostics for AML, now mandatory and expected to become more important in the future context of “precision” medicine.

show abstract

Section: Comments From the Scientific Steering Committeementioning

confidence: 99%

Section: Comments From the Scientific Steering Committeementioning

confidence: 99%

Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These factors contribute to a lower threshold for compromising the quality of life (QOL) due to a lower tolerance for systemic treatment. Often this group endures an early treatment discontinuation and can be undertreated for malignancy, as opposed to patients at younger ages [5]. As a result, the estimation of the treatment efficacy and adverse events in older populations within randomized controlled trials (RCTs) can lack precision, leading to an inaccurate replication of the real-world clinical environment [6].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy for older patients with cancer

Vargas

Al-Humiqani

Mata

et al. 2023

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of the review The aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients. Recent findings Studies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient. Summary Older adults remain underrepresented in clinical trials, including those involving immunotherapy. Therefore, efforts must be made to include more older patients in trials and to assess real-world evidence to inform decision-making.

show abstract

“…Presently, the standard curative treatment strategy for acute myeloid leukemia (AML) is comprised of intensive induction chemotherapy followed by consolidation treatment and allogeneic hematopoietic stem cell transplantation 1 . However, a significant amount of AML patients are unable to undergo such intensive treatment, owing to their advanced age, comorbidities and/or poor performance status 2 . These limitations are even more pronounced in AML patients at relapse due to increased morbidity related to previous treatment attempts, leading to a particularly poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic options

Schmid

Festl

Severin

et al. 2023

Preprint

View full text Add to dashboard Cite

Elderly or unfit patients with relapsed acute myeloid leukemia (AML) face a poor prognosis and are likely to rapidly exhaust all registered treatment options. Pharmacoscopy, an image-based ex vivo drug screening platform, has previously been suggested as a tool for treatment selection in AML. We used pharmacoscopy to generate personalized treatment recommendations for 30 relapse settings of 24 AML patients which exhausted all standard therapeutic options. We evaluated whether pharmacoscopy can be employed within the narrow timeframe available under an AML relapse setting, how often recommended regimens could be started and whether they provided durable clinical benefits. 17 of 30 screens (56.7%) resulted in patients receiving a recommended therapy, leading to promising trends in clinical response and survival. A drug regimen's integrated pharmacoscopy score proved to be an excellent predictor of clinical response: Patients receiving a regimen with above-median scores showed significantly higher rates of complete remission (OR 3.01, p < 0.0005) and significantly longer overall survival (ratio 3.39, p < 0.006). We conclude that pharmacoscopy is an efficient and valuable tool for therapy selection in AML at relapse and propose concrete measures to further improve clinical implementation.

show abstract

Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review

Cited by 15 publications

References 72 publications

Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey

Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey

Immunotherapy for older patients with cancer

Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic options

Contact Info

Product

Resources

About